Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Visx claims US first for CustomVue eye laser:

This article was originally published in Clinica

Executive Summary

Visx has received FDA approval for what it claims to be the first US-approved wavefront-guided laser treatment for hyperopia. The CustomVue laser vision correction procedure, which was also approved for treating astigmatism, uses the firm's WaveScan technology, a diagnostic system that captures a comprehensive "fingerprint" of each eye and generates an individualised treatment for each CustomVue procedure. "We believe this further advancement of laser vision correction technology will enhance our market leadership position, drive CustomVue conversions, and increase future revenue and profit opportunities," said Liz Davila, the Santa Clara, California firm's chairman and CEO.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT053910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel